Loading data for NTRB — first visit, this takes a few seconds.
Nutriband Inc. (NTRB)
NasdaqCM: NTRB
· Real-Time Price · USD
5.97
+0.34 (6.04%)
At close: Sep 11, 2026, 1:49 PM
The price, the headline numbers and the latest news, in one place.
Nutriband Inc. (NTRB) Stock Price, Analysis & Data
No data available
| Bid | 4 |
| Market Cap | 79.8M |
| Revenue (ttm) | 1.62M |
| Net Income (ttm) | -6.96M |
| 2.04 | |
| -0.49 | |
| n/a | |
| -28.56 | |
| P/B (ttm) | 15.00 |
| P/S (ttm) | 49.36 |
| Earnings Date | n/a |
| Ask | 7.29 |
| Volume | 96,192 |
| Avg. Volume (20D) | 21,546 |
| Open | 5.66 |
| Previous Close | 5.63 |
| Day's Range | 5.17 - 6.07 |
| 52-Week Range | 2.80 - 8.63 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in O...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees n/a
Stock Exchange NasdaqCM
Ticker Symbol NTRB
Website https://www.nutriband.com
Financial Performance
In 2026, Nutriband's revenue was 2.04M, a decrease of -4.81% compared to the previous year's 2.14M. Earnings were -8.23M, a decrease of -21.49%.
Financial StatementsEarnings Surprise
Nutriband has released their quarterly earnings on Apr 29, 2026:
- Revenue of $433.4K misses estimates by $0, with -35.06% YoY decline.
- EPS of -0.04 exceeds estimates by 1.85, with 92.16% YoY growth.
Page 1 of 2